登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT05482568,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Received >30 Gy chest radiation within 6 months prior to initial administration
排除标准第 5 条
The half-life of CYP3A4 suppressor, moderate inhibitor or strong inducer or moderate inducer is less than 3 or less than 14 days from the date of first drug use, and the shorter is selected
排除标准第 8 条
Received systemic immunosuppressant therapy within 14 days prior to the first study
排除标准第 9 条
Subjects who are participating in another clinical study or who have had their first dose less than 4 weeks since the end of the previous clinical study (last dose) or 5 half-lives of the study drug, whichever is shorter
排除标准第 20 条
The ECOG score is 0 or 1
入选标准第 3 条
There were active tuberculosis patients within 1 year before enrollment
排除标准第 17 条
Female subjects who are pregnant, breast-feeding, or planning to become pregnant during the study
排除标准第 24 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05482568,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Ability to give informed consent, signed and dated IRB/EC approved informed consent, willing and able to comply with treatment planning visits, tests and other procedural requirements When signing the informed consent, the age is 18-75 years old (including both ends), and there is no gender limitation The ECOG score is 0 or 1 The expected survival is ≥12 weeks Subjects with advanced or metastatic non-small cell lung cancer Formalin fixed, paraffin-embedded tumor tissue blocks or sections of unstained tumor specimens are provided Subjects who have failed prior standard care or are intolerant to standard care There is at least one measurable lesion Vital organs are functioning well Heart function is good Agree to birth control排除标准:Exclusion Criteria:
There are untreated or active central nervous system (CNS) tumor metastases Pleural, ascites, or pericardial effusion requiring intervention occurred within 7 days prior to initial administration Systemic antitumor therapy was performed 4 weeks prior to study initiation Prior treatment with antibody-conjugated drugs Received >30 Gy chest radiation within 6 months prior to initial administration Palliative radiotherapy was completed within 7 days prior to initial administration Failure to recover from toxicity and/or complications of previous interventions to nCI-CTCAE ≤1 The half-life of CYP3A4 suppressor, moderate inhibitor or strong inducer or moderate inducer is less than 3 or less than 14 days from the date of first drug use, and the shorter is selected Received systemic immunosuppressant therapy within 14 days prior to the first study Subjects with known or suspected interstitial pneumonia In the first study, failure to swallow, chronic diarrhea, gastroenteritis, intestinal obstruction, gastrointestinal perforation, postgastrectomy, or colitis, or other medical conditions or special conditions affecting drug administration and absorption occurred within 28 days prior to administration Presence of any active, known or suspected autoimmune disease Have poorly controlled or severe cardiovascular disease Previous or concurrent malignancy Subjects who developed a severe infection within 28 days prior to the first dose Active hepatitis B There were active tuberculosis patients within 1 year before enrollment There is a history of immunodeficiency Live attenuated vaccine was administered within 28 days prior to initial study administration or is expected to be administered during study treatment Subjects who are participating in another clinical study or who have had their first dose less than 4 weeks since the end of the previous clinical study (last dose) or 5 half-lives of the study drug, whichever is shorter Major surgery other than diagnosis or biopsy was performed within 28 days prior to initial administration People who are known to be allergic to sir-A1811, pyrrolitinib, or any of the components of SIR-1316 History of severe allergic reactions to other monoclonal antibody/fusion protein drugs Female subjects who are pregnant, breast-feeding, or planning to become pregnant during the study Uncontrolled mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse and detention Any other conditions that, in the investigator's judgment, may increase the risk of study participation, interfere with study results, or make study participation unsuitable
引自 ClinicalTrials.gov, NCT05482568, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05482568,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。